The advisory group consisted of Food and Drug Administration (FDA) and Vaccines and Related Biological Products Advisory Committee (VRBPAC) experts.

The group voted for a return to trivalent flu vaccines, similar to the WHO recommendation in September 2023.

They urged manufacturers to drop the Yamagata strain from 2024-25 vaccines since it has not been detected since 2020 in the US.

They also approved the WHO-recommended Northern Hemisphere strains for the US for the 2024-25 season.

However, all countries cannot switch to trivalent vaccines since it may still be circulating there or they may not have the means to switch to trivalent vaccines in such a short time.